AKT1 and B-cell chronic lymphocytic leukemia: Bendamustine has clinical activity in numerous cancer types (Keating et al, 2008) and AKT inhibitors have recently entered clinical trials including a study investigating the combination of bendamustine with MK2206 and rituximab in CLL patients (NCT01369849).